UK markets close in 4 hours 31 minutes
  • FTSE 100

    7,031.70
    +14.23 (+0.20%)
     
  • FTSE 250

    22,267.78
    -56.41 (-0.25%)
     
  • AIM

    1,222.18
    -7.62 (-0.62%)
     
  • GBP/EUR

    1.1666
    +0.0030 (+0.26%)
     
  • GBP/USD

    1.3876
    +0.0067 (+0.48%)
     
  • BTC-GBP

    23,419.79
    -1,225.15 (-4.97%)
     
  • CMC Crypto 200

    795.17
    -144.78 (-15.40%)
     
  • S&P 500

    4,166.45
    -55.41 (-1.31%)
     
  • DOW

    33,290.08
    -533.32 (-1.58%)
     
  • CRUDE OIL

    71.77
    +0.13 (+0.18%)
     
  • GOLD FUTURES

    1,784.00
    +15.00 (+0.85%)
     
  • NIKKEI 225

    28,010.93
    -953.15 (-3.29%)
     
  • HANG SENG

    28,489.00
    -312.27 (-1.08%)
     
  • DAX

    15,561.48
    +113.44 (+0.73%)
     
  • CAC 40

    6,588.92
    +19.76 (+0.30%)
     

Infant Bacterial Therapeutics CFO leaves the company

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
  • Oops!
    Something went wrong.
    Please try again later.

Infant Bacterial Therapeutics ABs CFO Daniel Mackey has decided to leave the company to pursue new challenges. He will remain in his current role during his notice period. Michael Owens will be acting CFO when Daniel leaves the company and until his replacement is in place. The recruitment process has already been initiated.

“I would like to take this opportunity to thank Daniel and wish him every success in the future”, says Staffan Strömberg, Chief Executive Officer of IBT.

About Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) is a pharmaceutical company with a product in Phase III with a vision to develop drugs influencing the infant microbiome, and thereby prevent or treat rare diseases affecting infants.

IBT is currently developing the drug candidate IBP-9414, for the prevention of necrotizing enterocolitis (“NEC”) and improvement of feeding tolerance in premature infants. IBP-9414 contains the active substance Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. The product portfolio also includes another project, IBP-1016, for the treatment of gastroschisis, a severe and rare disease affecting infants. By developing these drugs, IBT has the potential to fulfill unmet needs for diseases where there are currently no prevention or treatment therapies available.

Infant Bacterial Therapeutics AB (“IBT”) is a public company domiciled in Stockholm. The company’s class B-shares shares are listed on Nasdaq Stockholm, Mid-cap (IBT B).

For additional information please contact
Staffan Strömberg, CEO
Daniel Mackey, CFO
Infant Bacterial Therapeutics AB
Bryggargatan 10
111 21 Stockholm
Phone: +46 70 670 1226
info@ibtherapeutics.com
www.ibtherapeutics.com

Publication

The information was submitted for publication, through the agency of the contact persons set out above, at 16:30 CET on May 20, 2021.

Attachment


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting